Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Amortization of Deferred Charges (2020 - 2024)

Haemonetics (HAE) has 9 years of Amortization of Deferred Charges data on record, last reported at $782000.0 in Q1 2024.

  • For Q1 2024, Amortization of Deferred Charges fell 10.32% year-over-year to $782000.0; the TTM value through Mar 2024 reached $3.2 million, up 61.17%, while the annual FY2024 figure was $3.2 million, 61.17% up from the prior year.
  • Amortization of Deferred Charges reached $782000.0 in Q1 2024 per HAE's latest filing, roughly flat from $783000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $1.0 million in Q3 2021 and bottomed at -$484000.0 in Q4 2022.
  • Average Amortization of Deferred Charges over 5 years is $630500.0, with a median of $789500.0 recorded in 2021.
  • The widest YoY moves for Amortization of Deferred Charges: up 472.66% in 2022, down 160.96% in 2022.
  • A 5-year view of Amortization of Deferred Charges shows it stood at $139000.0 in 2020, then surged by 471.22% to $794000.0 in 2021, then decreased by 1.13% to $785000.0 in 2022, then decreased by 0.25% to $783000.0 in 2023, then fell by 0.13% to $782000.0 in 2024.
  • Per Business Quant database, its latest 3 readings for Amortization of Deferred Charges were $782000.0 in Q1 2024, $783000.0 in Q4 2023, and $780000.0 in Q3 2023.